Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Rhea-AI Summary
Aquestive Therapeutics (NASDAQ:AQST) announced that its management team will participate in four investor conferences in September 2026: the Wells Fargo Healthcare Conference on September 8, the Cantor Healthcare Conference on September 9, Citi’s 2026 Biopharma Back to School Summit on September 10, and the H.C. Wainwright 27th Annual Global Investor Conference on September 14-15.
According to Aquestive, webcasts of the Cantor fireside chat and the H.C. Wainwright presentation, along with 30-day replays, will be available on the Investors "Events and Presentation" section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – AQST
In the Sep 1 session, AQST gained 2.15%, reflecting a moderate positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 11 | Q2 earnings report | Negative | -4.1% | Quarterly results included continued losses despite higher revenue and reaffirmed guidance. |
| Aug 10 | Clinical data update | Positive | +8.9% | Anaphylm human factors and pharmacokinetic results supported planned NDA resubmission. |
| Jul 29 | Earnings date notice | Neutral | -4.3% | The company scheduled its second-quarter results and investor conference call. |
| Jul 07 | Investor conference participation | Neutral | +2.1% | Management announced participation in the Leerink Partners Therapeutics Forum. |
| May 13 | Q1 earnings report | Positive | +14.5% | Quarterly revenue growth and improved losses accompanied continued Anaphylm development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Responses varied: positive clinical and Q1 earnings news rose, while Q2 results fell; conference-related notices had mixed outcomes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:
- 2026 Wells Fargo Healthcare Conference: available to host investor meetings on Tuesday, September 8th
- Cantor Healthcare Conference: fireside chat at 3:20 pm ET and available to host investor meetings on Wednesday, September 9th
- Citi’s 2026 Biopharma Back to School Summit: available to host investor meetings Thursday, September 10th.
- H.C. Wainwright 27th Annual Global Investor Conference: presentation at 9:00 am ET on Monday, September 14th and available to host investor meetings September 14th and Tuesday, September 15th
Webcasts of the fireside chat at the Cantor Healthcare Conference and the presentation at the H.C. Wainwright 27h Annual Global Investor Conference will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidates, including Anaphylm™ (dibutepinephrine) sublingual film and AQST-108 (epinephrine prodrug) topical gel, through clinical development and approval by the U.S. Food and Drug Administration (FDA) for the respective targeted indications. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm and AQST-108, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Inquiries:
Brian Korb
astr partners
brian.korb@astrpartners.com
